| Stereochemistry | ACHIRAL |
| Molecular Formula | C19H16ClNO4 |
| Molecular Weight | 357.788 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CC(=O)N(O)C(COC2=CC=C(OC3=CC=C(Cl)C=C3)C=C2)=C1
InChI
InChIKey=UDYUIWXQUBNDHC-UHFFFAOYSA-N
InChI=1S/C19H16ClNO4/c1-13-10-15(21(23)19(22)11-13)12-24-16-6-8-18(9-7-16)25-17-4-2-14(20)3-5-17/h2-11,23H,12H2,1H3
| Molecular Formula | C19H16ClNO4 |
| Molecular Weight | 357.788 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Rilopirox (HOE 351) is a fungicidal antimycotic that was developed as an intravaginal antifungal with a long skin retention time and a strong killing effect on pathogenic yeasts. Its very low water solubility makes rilopirox a good candidate for an intravaginal antifungal. Potential applications may be in mucosal candida infections, tinea versicolor and seborrheic dermatitis. In addition, it has been suggested that rilopirox could be effective against oropharyngeal Candida infections, for example in AIDS patients. There is no information on current development of rilopirox.
